Fast Market Research

Recently Released Market Study: Rheumatic Disorders - Pipeline Review, H2 2012

Fast Market Research recommends "Rheumatic Disorders - Pipeline Review, H2 2012" from Global Markets Direct, now available

 

Boston, MA -- (ReleaseWire) -- 11/12/2012 -- Global Markets Direct's, 'Rheumatic Disorders - Pipeline Review, H2 2012', provides an overview of the Rheumatic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Rheumatic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatic Disorders. 'Rheumatic Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


- A snapshot of the global therapeutic scenario for Rheumatic Disorders.

- A review of the Rheumatic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Rheumatic Disorders pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Identify and understand important and diverse types of therapeutics under development for Rheumatic Disorders.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Rheumatic Disorders pipeline depth and focus of Rheumatic Disorders therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Autoimmune Disorders - Pipeline Review, H2 2012
- Leukocyte Disorders (White Blood Cell Disorders) - Pipeline Review, H2 2012
- Acne And Related Disorders - Pipeline Review, H2 2012
- Movement Disorders - Pipeline Review, H2 2012
- Inherited Metabolic Disorders - Pipeline Review, H2 2012
- Upper Respiratory Tract Disorders - Pipeline Review, H2 2012
- Muscle Wasting Disorders - Pipeline Review, H2 2012
- Sleep Disorders - Pipeline Review, H2 2012
- Growth Disorders - Pipeline Review, H2 2012
- Other Central Nervous System Disorders - Pipeline Review, H2 2012